{"id":5133,"date":"2026-10-16T10:49:31","date_gmt":"2026-10-16T10:49:31","guid":{"rendered":"https:\/\/nhdbio.com\/?p=5133"},"modified":"2026-10-16T10:49:31","modified_gmt":"2026-10-16T10:49:31","slug":"ss31-gga-plga-zebrafish-delivery-study","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/fr\/ss31-gga-plga-zebrafish-delivery-study\/","title":{"rendered":"Nanoparticules modifi\u00e9es par SS-31 : lire une exp\u00e9rience de d\u00e9livrance"},"content":{"rendered":"
\n

SS-31-Modified Nanoparticles: Reading a Delivery Experiment<\/h2>\n

See how SS-31, GGA and PLGA were combined in a zebrafish study, and why the findings differ from free-peptide effects.<\/p>\n

\"SS-31-Modified
Illustration \u00e9ditoriale, pas une photographie exp\u00e9rimentale.<\/figcaption><\/figure>\n

Identify the carrier, cargo and surface modification<\/h3>\n

The 2017 study used PLGA nanoparticles carrying geranylgeranylacetone, GGA, with SS-31 conjugated to the particles. PLGA forms the carrier; GGA is the cargo; SS-31 contributes to the investigated mitochondrial-targeting design. The parcel analogy helps explain the components, but does not imply perfectly precise biological delivery.<\/p>\n

Why zebrafish hair cells were studied<\/h3>\n

The researchers used zebrafish lateral-line sensory hair cells to investigate gentamicin-related damage, uptake and survival. This is an experimental sensory-cell model, not a human hearing trial. Its findings cannot be converted into an expected degree of hearing recovery in people.<\/p>\n

\"SS-31
Study-design schematic. Findings concern a drug-delivery system, not the isolated action of free SS-31.<\/figcaption><\/figure>\n

Delivery and protection are separate endpoints<\/h3>\n

Accumulation near mitochondria differs from a final protective outcome. The paper investigated localization, gentamicin uptake, mitochondrial membrane potential and hair-cell survival. A change in one endpoint cannot stand in for the others, and clearer localization does not guarantee better performance in every functional test.<\/p>\n

Why empty-carrier controls matter<\/h3>\n

The abstract reports favorable hair-cell survival with GGA-loaded, SS-31-modified particles, whereas blank formulations did not show the same protective potency. This distinguishes cargo, carrier and surface-modification contributions. The complete formulation's outcome should not all be assigned to free SS-31.<\/p>\n

What the figure does and does not show<\/h3>\n

The figure explains how the materials and model fit together. It does not estimate survival percentages from published image heights. Before quoting a numerical result, obtain the original values and check treatment groups, observation times and counting methods.<\/p>\n

Match the material request to the study<\/h3>\n

The SS-31 page concerns catalog research peptide. A project requiring SS-31-conjugated PLGA particles needs separate conjugation, loading and characterization specifications. The article does not establish that catalog SS-31 has the delivery performance of the published formulation.<\/p>\n

R\u00e9f\u00e9rences<\/h3>\n